X Bioscience PCL (BKK:XBIO) Total Liabilities : ฿586.9 Mil (As of Dec. 2024)

View and export this data going back to 2003. Start your Free Trial

What is X Bioscience PCL Total Liabilities?

X Bioscience PCL's Total Liabilities for the quarter that ended in Dec. 2024 was ฿586.9 Mil.

X Bioscience PCL's quarterly Total Liabilities declined from Jun. 2024 (฿609.87 Mil) to Sep. 2024 (฿544.00 Mil) but then increased from Sep. 2024 (฿544.00 Mil) to Dec. 2024 (฿586.93 Mil).

X Bioscience PCL's annual Total Liabilities declined from Dec. 2022 (฿597.55 Mil) to Dec. 2023 (฿556.58 Mil) but then increased from Dec. 2023 (฿556.58 Mil) to Dec. 2024 (฿586.93 Mil).

X Bioscience PCL Total Liabilities Historical Data

The historical data trend for X Bioscience PCL's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

X Bioscience PCL Total Liabilities Chart

X Bioscience PCL Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

332.44

647.19

597.55

556.58

586.93

X Bioscience PCL Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															556.58	586.90	609.87	544.00	586.93

X Bioscience PCL Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

X Bioscience PCL's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	433.265	+	(77.496	+	5.8850000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	64.885	+	5.395	+	0)
	=	586.9

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	1414.355	-	827.429
	=	586.9

X Bioscience PCL's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	433.265	+	(77.496	+	5.8850000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	64.885	+	5.395	+	0)
	=	586.9

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	1414.355	-	827.429
	=	586.9

X Bioscience PCL Total Liabilities Related Terms

Thank you for viewing the detailed overview of X Bioscience PCL's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

X Bioscience PCL Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Retail - Defensive » X Bioscience PCL (BKK:XBIO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

XBIO-W7:Thailand

Address

Phahon Yothin Road, No.304, Room No.1803-1806, 18th Floor, Vanit Place Aree Tower (Tower A, Sam Sen Nai, Bangkok, THA, 10400

Website

https://www.xbio.co.th

X Bioscience PCL is engaged in investment in food and beverages business and the group are engaged in selling food and beverages, and manufacturing and selling biological products. The group operates in two business segments: the food and beverage sales segment and the internal management services segment provided by the parent company. The group operates in a single geographic area, which is Thailand. The company's brand consists of Kagonaya, Bake, and Leboeuf.